Literature DB >> 11457493

Differential responses of human neuroblastoma and glioblastoma to apoptosis.

S Bursztajn1, J J Feng, A Nanda, S A Berman.   

Abstract

Staurosporine, a protein kinase and etoposide, a topoisomerase II inhibitor, are known to enhance apoptosis. The differential effects of these agents on T98G glioblastoma and SK-N-SH neuroblastoma, cell lines both derived from human tumors, have not been determined. We assessed cellular viability, DNA fragmentation and laddering, chromatin condensation, and Poly(ADP-ribose) polymerase (PARP) cleavage induced by these agents at a series of concentrations and times. In addition, to gain an understanding of the mechanism by which these agents work, we measured Protein Kinase C (PKC) activity. Staurosporine induced significant alterations in all apoptotic parameters tested in both cell lines. Etoposide induced apoptotic alterations similar to those caused by staurosporine in neuroblastoma but produced no detectable apoptotic changes in glioblastoma cells. Etoposide induced membrane but not cytosolic PKC activity in neuroblastoma but had no effect on PKC activity in glioblastoma. Our results show that the induction of apoptosis is cell type dependent. PKC activity appears to be crucial in the initiation of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457493     DOI: 10.1016/s0169-328x(01)00123-1

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  2 in total

1.  Bcl-2 regulator FKBP38 is activated by Ca2+/calmodulin.

Authors:  Frank Edlich; Matthias Weiwad; Frank Erdmann; Jörg Fanghänel; Franziska Jarczowski; Jens-Ulrich Rahfeld; Gunter Fischer
Journal:  EMBO J       Date:  2005-06-30       Impact factor: 11.598

2.  VCP mutations causing frontotemporal lobar degeneration disrupt localization of TDP-43 and induce cell death.

Authors:  Michael A Gitcho; Jeffrey Strider; Deborah Carter; Lisa Taylor-Reinwald; Mark S Forman; Alison M Goate; Nigel J Cairns
Journal:  J Biol Chem       Date:  2009-02-23       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.